Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 214 citing articles:

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2024) Vol. 149, Iss. 8
Open Access | Times Cited: 782
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 393-406
Closed Access | Times Cited: 311
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 4, pp. 367-378
Open Access | Times Cited: 165
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 160
Current treatment of non‐alcoholic fatty liver disease
Rafael Paternostro, Michael Trauner
Journal of Internal Medicine (2022) Vol. 292, Iss. 2, pp. 190-204
Open Access | Times Cited: 156
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 83
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 2, pp. 180-191
Open Access | Times Cited: 79
The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome
Krzysztof Bednarz, Karolina Kowalczyk, Marlena Cwynar, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4334-4334
Open Access | Times Cited: 76
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 2, pp. 179-191
Open Access | Times Cited: 71
An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2023) Vol. 161, pp. 170939-170939
Open Access | Times Cited: 70
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, et al.
Metabolism (2024) Vol. 154, pp. 155835-155835
Open Access | Times Cited: 68
Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15473-15473
Open Access | Times Cited: 45
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies
Erica Vetrano, Luca Rinaldi, Andrea Mormone, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 468-468
Open Access | Times Cited: 41
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 29
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
Le Zhang, Mortada El‐Shabrawi, Louise A. Baur, et al.
Med (2024) Vol. 5, Iss. 7, pp. 797-815.e2
Closed Access | Times Cited: 16
Mitochondrial targeted therapy in MAFLD
Sien Lai, Dongsheng Tang, Juan Feng
Biochemical and Biophysical Research Communications (2025) Vol. 753, pp. 151498-151498
Closed Access | Times Cited: 1
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Hyun-Mi Kim, Da Som Lee, Tae Hyeon An, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4495-4495
Open Access | Times Cited: 99
Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
Karolina Drożdż, Katarzyna Nabrdalik, Weronika Hajzler, et al.
Nutrients (2021) Vol. 14, Iss. 1, pp. 103-103
Open Access | Times Cited: 71
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis
Benedikt Simbrunner, Michael Trauner, Thomas Reiberger
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 10, pp. 1243-1262
Open Access | Times Cited: 69
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Amedeo Lonardo, Juan Pablo Arab, Marco Arrese
Advances in Therapy (2021) Vol. 38, Iss. 5, pp. 2130-2158
Open Access | Times Cited: 66
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)
Samit Ghosal, Debasis Datta, Binayak Sinha
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 65
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
Cheng Han Ng, Kai En Chan, Yip Han Chin, et al.
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 3, pp. 565-574
Open Access | Times Cited: 64
Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis
Shaza Asif, Ri Youn Kim, Thet Fatica, et al.
Molecular Metabolism (2022) Vol. 61, pp. 101494-101494
Open Access | Times Cited: 60
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
Elke Roeb, Ali Canbay, Frank Tacke, et al.
Zeitschrift für Gastroenterologie (2022) Vol. 60, Iss. 09, pp. 1346-1421
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top